OrsoBio

OrsoBio is a biotechnology company developing therapies for people with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, and metabolic dysfunction-associated steatohepatitis (MASH). Its research focuses on fundamental pathways of energy metabolism, with the goal of restoring energy homeostasis and improving clinical outcomes. The company describes its approach as addressing the underlying causes of metabolic disease and prioritizing conditions associated with substantial morbidity and mortality.

OrsoBio’s pipeline includes investigational, first-in-class therapies, including TLC-2716, an LXR inverse agonist studied in severe hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease, and TLC-1180, a protonophore featured in research with semaglutide. These programs reflect the company’s focus on developing novel treatment approaches for complex metabolic conditions.

The team brings together physicians, scientists, and biotechnology leaders with decades of clinical and drug development experience. OrsoBio also shares research and company updates through scientific publications, conference presentations, and news announcements. Its work includes collaboration on research using human liver organoids to investigate the genetic basis of metabolic liver disease and opportunities for tailored therapeutic development.